Stock Market & Financial Investment News

BioCryst price target raised to $24 from $21 at H.C. WainwrightH.C. Wainwright raised its price target for BioCryst shares to $24 saying two overhangs have been removed with the positive Phase 2a data for oral kallikrein inhibitor 4161 and the recent equity financing. The firm reiterates a Buy rating on the stock.